Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Enlivex Therapeutics Ltd. (ENLV) had Weighted-Average Shares Outstanding (Diluted) of 20.51M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-15.01M |
|
-- |
|
-- |
|
$15.89M |
|
$-15.89M |
|
$0.87M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.01M |
|
$-15.89M |
|
$-15.34M |
|
20.51M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
20.51M |
$-0.73 |
|
$-0.73 |
|
| Balance Sheet Financials | |
$25.99M |
|
$0.62M |
|
$1.69M |
|
$27.69M |
|
$3.80M |
|
-- |
|
$0.30M |
|
$4.10M |
|
$23.59M |
|
$23.59M |
|
$23.59M |
|
23.65M |
|
| Cash Flow Statement Financials | |
$-13.01M |
|
$9.06M |
|
$6.45M |
|
$1.23M |
|
$3.73M |
|
$2.50M |
|
$2.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.84 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.93M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-63.65% |
|
-63.65% |
|
-54.23% |
|
-63.65% |
|
$1.00 |
|
$-0.63 |
|
$-0.63 |
|